Smart Technology Facilitated Patient-centered Venous Thromboembolism Management
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: mobile venous thromboembolism application (mVTEA).
- Кому может быть актуально
- Состояния в реестре: Venous Thromboembolism, Digital Health, Health Education. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Китай
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management: A Multicenter Cohort Study
Обзор
Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention. The objective of this study is to observe the long-term effect of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on thromboprophylaxis, and establish a foundation of evidence for managing patients with high-risk VTE.
Вмешательства
- Устройство mobile venous thromboembolism application (mVTEA)
mVTEA will assist in the management of patients with high-risk of VTE during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their c
Первичные конечные точки
- VTE-related composite event [Срок оценки: At 1-year follow-up]
Вторичные конечные точки (7)
- VTE-KAP questionnaire score [Срок оценки: At 3, 12, and 24-month follow-up]
- Generic quality of life [Срок оценки: At 3, 12, and 24-month follow-up]
- VTE events [Срок оценки: At 3, 6, 12, and 24-month follow-up]
- Major bleeding [Срок оценки: At 3, 6, 12, and 24-month follow-up]
- VTE-related hospitalization [Срок оценки: At 3, 6, 12, and 24-month follow-up]
- New-onset of atrial fibrillation or atrial flutter [Срок оценки: At 3, 6, 12, and 24-month follow-up]
- Death [Срок оценки: At 3, 6, 12, and 24-month follow-up]
Критерии участия
Критерии включения
- Inpatients ≥18 years of age at admission;
- At high-risk of VTE at discharge: Padua score ≥4 for medical patients and Caprini score ≥5 for surgical patients;
- Signed informed consent.
Критерии исключения
- Diagnosis of VTE at discharge;
- Mental disorder or combination of other serious diseases leading to incapacity for independent living;
- Inability to use smartphones, computer tablets and other smart devices;
- Being pregnant or breastfeeding;
- Have participated in similar trials or are undergoing other clinical trials.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Не применимо
- Модель
- Одна группа
- Маскирование
- Открытое
- Основная цель
- Профилактика
Центры проведения
Китай · 1 центр
- Sixth Medical Center of Chinese PLA General Hospital — Пекин
Публикации
- Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008 Apr;6(4):601-8. doi: 10.1111/j.1538-7836.2008.02908.x. Epub 2008 Jan 17. PMID 18208538
- Kang MJ, Ryoo BY, Ryu MH, Koo DH, Chang HM, Lee JL, Kim TW, Kang YK. Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience. Eur J Cancer. 2012 Mar;48(4):492-500. doi: 10.1016/j.ejca.2011.11.016. Epub 2011 Dec 12. PMID 22169121
- Henke PK, Kahn SR, Pannucci CJ, Secemksy EA, Evans NS, Khorana AA, Creager MA, Pradhan AD; American Heart Association Advocacy Coordinating Committee. Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association. Circulation. 2020 Jun 16;141(24):e914-e931. doi: 10.1161/CIR.0000000000000769. Epub 2020 May 7. PMID 32375490
Идентификаторы
NCT: NCT06350344 · HZKY-PJ-2024-8-2